Gene-function studies in systemic lupus erythematosus

Nature Reviews Rheumatology

Volumn 9, Issue 8, 2013, Pages 476-484

  Crispín, José C ^a   Hedrich, Christian M ^a   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLESTERASE; CD11B ANTIGEN; CD150 ANTIGEN; CD22 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C4; FC RECEPTOR; MICRORNA; PHOSPHOPROTEIN PHOSPHATASE 2A; SIALIC ACID O ACETYLESTERASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; COMPLEMENT DEFICIENCY; COPY NUMBER VARIATION; CYTOKINE PRODUCTION; DNA METHYLATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; ITGAM GENE; MISSENSE MUTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIAE GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREX1 GENE;

EID: 84881155922     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.78     Document Type: Review

References (105)

1. Harley, J. B., Kelly, J. A. & Kaufman, K. M. Unraveling the genetics of systemic lupus erythematosus. Springer Semin. Immunopathol 28, 119-130 (2006).
2. Alarcon-Segovia, D. et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 52, 1138-1147 (2005).
3. Deapen, D. et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35, 311-318 (1992).
4. Harley, J. B. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet 40, 204-210 (2008).
5. Hom, G. et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358, 900-909 (2008).
6. Kozyrev, S. V. et al. Functional variants in the B cell gene BANK1 are associated with systemic lupus erythematosus. Nat. Genet. 40, 211-216 (2008).
7. Moser, K. L., Kelly, J. A., Lessard, C. J. & Harley, J. B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10, 373-379 (2009).
8. Sestak, A. L., Furnrohr, B. G., Harley, J. B., Merrill, J. T. & Namjou, B. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann. Rheum. Dis. 70 (Suppl. 1), i37-i43 (2011).
9. Harley, I. T., Kaufman, K. M., Langefeld, C. D., Harley, J. B. & Kelly, J. A. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat. Rev. Genet. 10, 285-290 (2009).
10. Atkinson, J. P. Complement deficiency: predisposing factor to autoimmune syndromes. Clin. Exp. Rheumatol. 7 (Suppl. 3), S95-S101 (1989).
11. Ptacek, T., Li, X., Kelley, J. M. & Edberg, J. C. Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus. Cytogenet. Genome Res. 123, 142-147 (2008).
12. Yang, Y. et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am. J. Hum. Gene 80, 1037-1054 (2007).
13. Aitman, T. J. et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439, 851-855 (2006).
14. Fanciulli, M. et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 39, 721-723 (2007).
15. Cook, H. T. & Botto, M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2, 330-337 (2006).
16. Wu, Y. L. et al. Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet. Genome Res. 123, 131-141 (2008).
17. Manderson, A. P., Botto, M. & Walport, M. J. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22, 431-456 (2004).
18. Truedsson, L., Bengtsson, A. A. & Sturfelt, G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40, 560-566 (2007).
19. Davies, K. A., Peters, A. M., Beynon, H. L. & Walport, M. J. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J. Clin. Invest. 90, 2075-2083 (1992).
20. Korb, L. C. & Ahearn, J. M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J. Immunol. 158, 4525-4528 (1997).
21. Botto, M. et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19, 56-59 (1998).
22. Bussone, G. & Mouthon, L. Autoimmune manifestations in primary immune deficiencies. Autoimmun. Rev. 8, 332-336 (2009).
23. Carroll, M. C. A protective role for innate immunity in systemic lupus erythematosus. Nat. Rev. Immunol. 4, 825-831 (2004).
24. Figueroa, J. E. & Densen, P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4, 359-395 (1991).
25. Kavanagh, D. et al. New roles for the major human 3' 5' exonuclease TREX1 in human disease. Cell Cycle 7, 1718-1725 (2008).
26. Hedrich, C. M. et al. Chilblain lupus erythematosus - a review of literature. Clin. Rheumatol. 27, 949-954 (2008).
27. Lee-Kirsch, M. A. et al. A mutation in TREX1 that impairs susceptibility to granzyme A mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85, 531-537 (2007).
28. Gunther, C., Meurer, M., Stein, A., Viehweg, A. & Lee-Kirsch, M. A. Familial chilblain lupus - a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology 219, 162-166 (2009).
29. Hedrich, C. M. & Tsokos, G. C. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol. Med. 17, 714-724 (2011).
30. Ablasser, A., Hertrich, C., Waßermann, R. & Hornung, V. Nucleic acid driven sterile inflammation. Clin. Immunol. http://dx.doi.org/10.1016/j. clim.2013.01.003.
31. Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134, 587-598 (2008).
32. Lee-Kirsch, M. A. et al. Mutations in the gene encoding the 3' 5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39, 1065-1067 (2007).
33. Namjou, B. et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12, 270-279 (2011).
34. Ewen, C. L., Kane, K. P. & Bleackley, R. C. A quarter century of granzymes. Cell Death Differ. 19, 28-35 (2012).
35. Lieberman, J. Granzyme A activates another way to die. Immunol. Rev. 235, 93-104 (2010).
36. Chowdhury, D. et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23 H1 to degrade DNA during granzyme A mediated cell death. Mol. Cell 23, 133-142 (2006).
37. Ramantani, G. et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutieres syndrome. Arthritis Rheum. 62, 1469-1477 (2010).
38. Richards, A. et al. C terminal truncations in human 3' 5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet. 39, 1068-1070 (2007).
39. O'Keefe, T. L., Williams, G. T., Davies, S. L. & Neuberger, M. S. Hyperresponsive B cells in CD22-deficient mice. Science 274, 798-801 (1996).
40. O'Keefe, T. L., Williams, G. T., Batista, F. D. & Neuberger, M. S. Deficiency in CD22, a B cell specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J. Exp. Med. 189, 1307-1313 (1999).
41. Sjoberg, E. R., Powell, L. D., Klein, A. & Varki, A. Natural ligands of the B cell adhesion molecule CD22β can be masked by 9 O acetylation of sialic acids. J. Cell Biol. 126, 549-562 (1994).
42. Guimaraes, M. J. et al. Molecular cloning and characterization of lysosomal sialic acid O acetylesterase. J. Biol. Chem. 271, 13697-13705 (1996).
43. Cariappa, A. et al. B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9 O acetyl sialic acid esterase. J. Exp. Med. 206, 125-138 (2009).
44. Surolia, I. et al. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466, 243-247 (2010).
45. Hunt, K. A. et al. Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nat. Genet. 44, 3-5 (2012).
46. Chellappa, V. et al. M89V sialic acid acetyl esterase (SIAE) and all other non-synonymous common variants of this gene are catalytically normal. PLoS ONE 8, e53453 (2013).
47. Nath, S. K. et al. A nonsynonymous functional variant in integrin-αM (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat. Genet 40, 152-154 (2008).
48. Phillipson, M. et al. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J. Exp. Med. 203, 2569-2575 (2006).
49. Rhodes, B. et al. The rs1143679 (R77H) lupus associated variant of ITGAM (CD11b) impairs complement receptor 3 mediated functions in human monocytes. Ann. Rheum. Dis 71, 2028-2034 (2012).
50. MacPherson, M., Lek, H. S., Prescott, A. & Fagerholm, S. C. A systemic lupus erythematosus-associated R77H substitution in the CD11b chain of the Mac 1 integrin compromises leukocyte adhesion and phagocytosis. J. Biol. Chem. 286, 17303-17310 (2011).
51. Rosetti, F. et al. Human lupus serum induces neutrophil-mediated organ damage in mice that is enabled by Mac 1 deficiency. J. Immunol. 189, 3714-3723 (2012).
52. Liu, Z. & Davidson, A. Taming lupus - a new understanding of pathogenesis is leading to clinical advances. Nat. Med. 18, 871-882 (2012).
53. Alarcon, G. S. et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med. 3, e396 (2006).
54. Brown, E. E., Edberg, J. C. & Kimberly, R. P. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 40, 567-581 (2007).
55. Nimmerjahn, F. & Ravetch, J. V. Fc-receptors as regulators of immunity. Adv. Immunol. 96, 179-204 (2007).
56. Chen, K. et al. Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo. Blood 120, 4421-4431 (2012).
57. Mueller, M. et al. Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locus. Am. J. Hum. Genet. 92, 28-40 (2013).
58. van der Pol, W. L. & van de Winkel, J. G. J. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 48, 222-232 (1998).
59. Katsiari, C. G., Kyttaris, V. C., Juang, Y. T. & Tsokos, G. C. Protein phosphatase 2A is a negative regulator of IL 2 production in patients with systemic lupus erythematosus. J. Clin. Invest. 115, 3193-3204 (2005).
60. Janssens, V., Longin, S. & Goris, J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem. Sci 33, 113-121 (2008).
61. Juang, Y. T. et al. PP2A dephosphorylates Elf 1 and determines the expression of CD3ζ and FcRγ in human systemic lupus erythematosus T cells. J. Immunol. 181, 3658-3664 (2008).
62. Juang, Y. T. et al. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP 1 and reflects disease activity in patients with systemic lupus erythematosus. J Biol. Chem. 286, 1795-1801 (2011).
63. Tan, W. et al. Association of PPP2CA polymorphisms with SLE susceptibility in multiple ethnic groups. Arthritis Rheum. 63, 2755-2763 (2011).
64. Sunahori, K., Juang, Y. T. & Tsokos, G. C. Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J. Immunol. 182, 1500-1508 (2009).
65. Sunahori, K., Juang, Y. T., Kyttaris, V. C. & Tsokos, G. C. Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus. J. Immunol. 186, 4508-4517 (2011).
66. Crispin, J. C. et al. Cutting edge: Protein phosphatase 2A confers susceptibility to autoimmune disease through an IL 17 dependent mechanism. J. Immunol. 188, 3567-3571 (2012).
67. Detre, C., Keszei, M., Romero, X., Tsokos, G. C. & Terhorst, C. SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. Semin. Immunopathol 32, 157-171 (2010).
68. Moser, K. L. et al. Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41. Arthritis Rheum. 42, 1902-1907 (1999).
69. Shai, R. et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum. Mol. Genet. 8, 639-644 (1999).
70. Tsao, B. P. et al. Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 46, 2928-2936 (2002).
71. Vyse, T. J. et al. Mapping autoimmune disease genes in humans: lessons from IBD and SLE. Novartis Found. Symp. 267, 94-107 (2005).
72. Rozzo, S. J., Vyse, T. J., Drake, C. G. & Kotzin, B. L. Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. Proc. Natl Acad. Sci. USA 93, 15164-15168 (1996).
73. Kono, D. H. et al. Lupus susceptibility loci in New Zealand mice. Proc. Natl Acad. Sci. USA 91, 10168-10172 (1994).
74. Hogarth, M. B. et al. Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J. Immunol. 161, 2753-2761 (1998).
75. Chatterjee, M. et al. Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation. J. Immunol. 188, 1206-1212 (2012).
76. Chatterjee, M. et al. CD3 T cell receptor co-stimulation through SLAMF3 and SLAMF6 receptors enhances RORγt recruitment to the IL17A promoter in human T lymphocytes. J. Biol. Chem. 287, 38168-38177 (2012).
77. Scheinbart, L. S., Johnson, M. A., Gross, L. A., Edelstein, S. R. & Richardson, B. C. Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol. 18, 530-534 (1991).
78. Oelke, K. et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 50, 1850-1860 (2004).
79. Wilson, C. B., Rowell, E. & Sekimata, M. Epigenetic control of T helper cell differentiation. Nat. Rev. Immunol. 9, 91-105 (2009).
80. Ballestar, E., Esteller, M. & Richardson, B. C. The epigenetic face of systemic lupus erythematosus. J. Immunol. 176, 7143-7147 (2006).
81. Zhao, M. et al. Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. J. Autoimmun. 35, 58-69 (2010).
82. Zhang, Y., Zhao, M., Sawalha, A. H., Richardson, B. & Lu, Q. Impaired DNA methylation and its mechanisms in CD4+ T cells of systemic lupus erythematosus. J. Autoimmun. 41, 92-99 (2013).
83. Yung, R. et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J. Clin. Invest. 97, 2866-2871 (1996).
84. Brenner, C. & Fuks, F. A methylation rendezvous: reader meets writers. Dev. Cell 12, 843-844 (2007).
85. Brenner, C. & Fuks, F. DNA methyltransferases: facts, clues, mysteries. Curr. Top. Microbiol. Immunol. 301, 45-66 (2006).
86. Renaudineau, Y. & Youinou, P. Epigenetics and autoimmunity, with special emphasis on methylation. Keio J. Med. 60, 10-16 (2011).
87. Ballestar, E. Epigenetic alterations in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 7, 263-271 (2011).
88. Hedrich, C. M., Rauen, T. & Tsokos, G. C. cAMP-responsive element modulator (CREM)α protein signaling mediates epigenetic remodeling of the human interleukin 2 gene: implications in systemic lupus erythematosus. J. Biol. Chem 286, 43429-43436 (2011).
89. Hedrich, C. M. et al. cAMP response element modulator α controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc. Natl Acad. Sci. USA 109, 16606-16611 (2012).
90. Liu, Y., Chen, Y. & Richardson, B. Decreased DNA methyltransferase levels contribute to abnormal gene expression in "senescent" CD4+CD28- T cells. Clin. Immunol. 132, 257-265 (2009).
91. Lal, G. et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182, 259-273 (2009).
92. Zhao, M. et al. Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 931018 (2010).
93. Rauen, T., Hedrich, C. M., Juang, Y. T., Tenbrock, K. & Tsokos, G. C. cAMP-responsive element modulator (CREM)α protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin 17A gene locus in patients with systemic lupus erythematosus. J. Biol. Chem 286, 43437-43446 (2011).
94. Singer, N. G. et al. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology 88, 537-543 (1996).
95. Lu, Q. et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 46, 1282-1291 (2002).
96. Lu, Q., Wu, A. & Richardson, B. C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 174, 6212-6219 (2005).
97. Lu, Q. et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179, 6352-6358 (2007).
98. Kaplan, M. J., Lu, Q., Wu, A., Attwood, J. & Richardson, B. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J. Immunol. 172, 3652-3661 (2004).
99. Basu, D. et al. Stimulatory and inhibitory killer Ig like receptor molecules are expressed and functional on lupus T cells. J. Immunol. 183, 3481-3487 (2009).
100. Chen, Y., Gorelik, G. J., Strickland, F. M. & Richardson, B. C. Decreased ERK and JNK signaling contribute to gene overexpression in "senescent" CD4+CD28- T cells through epigenetic mechanisms. J. Leukoc. Biol. 87, 137-145 (2010).
101. Liu, Y., Kuick, R., Hanash, S. & Richardson, B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin. Immunol. 130, 213-224 (2009).
102. Tang, Y. et al. MicroRNA 146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 60, 1065-1075 (2009).
103. Amarilyo, G. & La, C. A. miRNA in systemic lupus erythematosus. Clin. Immunol. 144, 26-31 (2012).
104. Fan, W. et al. Identification of microRNA 31 as a novel regulator contributing to impaired interleukin 2 production in T cells from patients with systemic lupus erythematosus. Arthritis Rheum. 64, 3715-3725 (2012).
105. Zhu, S. et al. The microRNA miR 23b suppresses IL 17 associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat. Med. 18, 1077-1086 (2012).